# US 2025/0367153 A1 · Composition and application thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0367153 A1
- Document ID: US20250367153A1
- Status: Published application
- Kind: A1
- Application number: 19/220,905
- Filed: 2025-05-28
- Published: 2025-12-04
- Earliest claimed: 2024-05-28
- Assignees: SyneuRx International (Taiwan) Corp.
- Applicants: Syneurx International (Taiwan) Corp.
- Inventors: Guo-Chuan TSAI; Wei-Hua CHANG; Lu-Ping LU; Chi-Sheng KUO; Xiao-Yi ZHUANG
- Web page: https://patentgrep.com/patent/US20250367153A1

## CPC

- A61K 31/198: Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00)
- A61K 31/047: having two or more hydroxy groups, e.g. sorbitol
- A61K 31/185: Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids (hydroxamic acids A61K31/16; peroxy acids A61K31/327)
- A61K 31/19: Carboxylic acids, e.g. valproic acid (salicylic acid A61K31/60)
- A61K 31/192: having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid {(cannabinoids A61K31/658)}
- A61K 31/197: the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid (carnitine A61K31/205)
- A61K 31/202: having three or more double bonds, e.g. linolenic (eicosanoids, e.g. leukotrienes A61K31/557)
- A61K 31/405: Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
- A61K 31/42: Oxazoles
- A61K 31/455: Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
- A61K 31/4748: forming part of bridged ring systems (strychnine A61K31/475; morphinan derivatives A61K31/485)
- A61K 31/685: one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
- A61K 31/7034: attached to a carbocyclic compound, e.g. phloridzin
- A61K 35/744: Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K 35/745: Bifidobacteria
- A61K 35/747: Lactobacilli, e.g. L. acidophilus or L. brevis
- A61K 36/53: Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K 36/54: Lauraceae (Laurel family), e.g. cinnamon or sassafras
- A61K 36/9066: Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 25/20: Hypnotics; Sedatives
- A61P 25/24: Antidepressants
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61K 2035/115: {Probiotics}
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

A composition, comprising a D-amino acid oxidase (DAAO) inhibitor and a N-methyl-D-aspartate (NMDA) modulator. Also provided herein are the method of the uses of by administering to a subject in need thereof an effective amount of the composition.

## Claims

### Claim 1

A composition, comprising:
a D-amino acid oxidase (DAAO) inhibitor; and
a N-methyl-D-aspartate (NMDA) modulator.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the DAAO inhibitor is selected from a group consisting of cinnamon extract, sodium benzoate, lithium benzoate, benzoic acid, sorbic acid, cinnamic acid, and tannic acid.

### Claim 3 (depends on 1)

The composition of claim 1, wherein the NMDA modulator is selected from a group consisting of glycine, sarcosine, dimethylglycine (DMG), trimethylglycine (TMG), D-phenylalanine, L-phenylalanine, DL-phenylalanine, phosphatidylserine, D-serine, L-serine, DL-serine, D-alanine, L-alanine, DL-alanine, D-cycloserine, L-cycloserine, DL-cycloserine, a probiotic composition, taurine, nicotinamide, tryptophan, threonine, γ-aminobutyric acid (GABA), tyrosine, 5-hydroxytryptophan (5HTP), docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA), lutein, lemon balm extract, and tumeric extract.

### Claim 4 (depends on 2)

The composition of claim 2, wherein the cinnamon extract is extracted from bark or leaf of Cinnamomum cassia, Cinnamomum austrosinense, Cinnamomum brevipedunculatum, Cinnamomum burmannii, Cinnamomum insularimontanum, Cinnamomum kotoense, Cinnamomum macrostemon, Cinnamomum osmophloeum, Cinnamomum reticulatum, Cinnamomum sericeum, Cinnamomum subavenium, Cinnamomum temufolium nervosum, Cinnamomum verum, or Cinnamomum loureiroi.

### Claim 5 (depends on 3)

The composition of claim 3, a probiotic composition comprising a plurality of probiotic strains selected from the group consisting of Lactobacillus acidophilus, Lactobacillus casei, Lactobacillus rhamnosus, Lactobacillus plantarum, Lactobacillus reuteri, Lactobacillus fermentum, Lactobacillus salivarius, Lactobacillus bulgaricus, Lactobacillus brevis, Lactobacillus paracasei, Lactobacillus gasseri, Lactobacillus johnsonii, Bacillus coagulans, Bifidobacterium adolescentis, Bifidobacterium animalis subsp. lactis, Bifidobacterium bifidum, Bifidobacterium breve, Bifidobacterium longum, Bifidobacterium infantis, Bifidobacterium lactis, Bifidobacterium pseudocatenulatum, Bifidobacterium thermophilum, Bifidobacterium pseudolongum or Clostridium buyricum.

### Claim 6 (depends on 3)

The composition of claim 3, wherein the probiotic count is 1×106 to 1×1012 CFU.

### Claim 7 (depends on 3)

The composition of claim 3, wherein the probiotic count is 1×109 to 1×1011 CFU.

### Claim 8 (depends on 1)

The composition of claim 1, further comprising a pharmaceutically acceptable excipient, carrier, diluent, binder, additive, filler, lubricant, nutrient, or a mixture thereof.

### Claim 9 (depends on 1)

The composition of claim 1, wherein the weight ratio of the DAAO inhibitor to the NMDA modulator is 1:100 to 100:1.

### Claim 10 (depends on 1)

The composition of claim 1, wherein the weight ratio of the DAAO inhibitor to the NMDA modulator is 1:50 to 50:1.

### Claim 11 (depends on 10)

The composition of claim 10, wherein the DAAO inhibitor is selected from the group consisting of cinnamon extract, sodium benzoate, cinnamic acid, and tannic acid, the NMDA modulator is selected from a group consisting of glycine, sarcosine, dimethylglycine (DMG), DL-serine, DL-alanine, and DL-cycloserine, and the weight ratio of the DAAO inhibitor to the NMDA modulator is 1:50 to 50:1.

### Claim 12 (depends on 10)

The composition of claim 10, wherein the DAAO inhibitor is selected from the group consisting of cinnamon extract, sodium benzoate, cinnamic acid, and tannic acid, the NMDA modulator is selected from a group consisting of glycine, sarcosine, dimethylglycine (DMG), D-serine, D-alanine, and D-cycloserine, and the weight ratio of the DAAO inhibitor to the NMDA modulator is 1:50 to 50:1.

### Claim 13 (depends on 12)

The composition of claim 12, wherein the DAAO inhibitor is selected from the group consisting of cinnamon extract, sodium benzoate, cinnamic acid, and tannic acid, the NMDA modulator is selected from a group consisting of glycine, sarcosine, dimethylglycine (DMG), D-serine, D-alanine, and D-cycloserine, and the weight ratio of the DAAO inhibitor to the NMDA modulator is 1:5 to 5:1.

### Claim 14 (depends on 1)

The composition of claim 1, wherein the composition is a pharmaceutical composition, a nutraceutical composition, a medical food, a health food, a health supplement, or a food additive.

### Claim 15 (depends on 1)

The composition of claim 1, wherein the composition is formulated in a form of tablet, pill, capsule, powder, granule, solution, suspension, soft chew, or gel.

### Claim 16 (depends on 1)

A method for treating, preventing, or delaying the onset of the psychiatric disorder or the central nervous system (CNS) disorder, comprising administering an effective amount of the composition of claim 1 to a subject in need thereof.

### Claim 17 (depends on 16)

The method of claim 16, wherein the psychiatric disorder is selected from a group consisting of depressive disorder, major depression, anhedonia, eating disorder, elimination disorder, feeding disorder, depression, dysthymia, mood disorder, anxiety disorder, personality disorder, addictive behavior, obsessive-compulsive and related disorder, trauma- and stressor-related disorders, dissociative disorder, sleep-wake disorder, sleep disorder, insomnia, somatic symptom and related disorder, social anxiety disorder, depression-related syndrome, symptom of depression due to a physical disorder, and drug-induced symptom of depression.

### Claim 18 (depends on 16)

The method of claim 16, wherein the CNS disorder is selected from a group consisting of schizophrenia, bipolar disorder (BD), attention-deficit disorder, attention-deficit hyperactivity disorder (ADHD), obsessive compulsive disorder (OCD), Tourette's syndrome, blepharospasm, post-traumatic stress disorder (PTSD), addiction disorder, psychotic disorder, panic disorder, autism spectrum disorder (ASD), Asperger's disorder, Alzheimer's disease, mild cognitive disorder (MCI), benign forgetfulness, vascular dementia, dementia with Lewy bodies (DLB), Huntington's disease (HD), premenstrual syndrome, nocturnal enuresis, non-epileptic seizures, mild cognitive impairment, mania, learning disorder, pain, Parkinson's disease, Duchenne muscular dystrophy, stoke, closed head injury, memory deficits, frontotemporal dementia (FTD), multiple sclerosis, amyotrophic lateral sclerosis (ALS), Lyme borreliosis, tick-borne diseases (TBD), fragile X syndrome (FXS), and traumatic brain injury.

### Claim 19 (depends on 1, 16)

The method of claim 16, wherein the DAAO inhibitor of the composition of claim 1 is selected from a group consisting of cinnamon extract, sodium benzoate, lithium benzoate, benzoic acid, sorbic acid, cinnamic acid, and tannic acid.

### Claim 20 (depends on 16)

The method of claim 16, wherein the NMDA modulator is selected from a group consisting of glycine, sarcosine, dimethylglycine (DMG), trimethylglycine (TMG), D-phenylalanine, L-phenylalanine, DL-phenylalanine, phosphatidylserine, D-serine, L-serine, DL-serine, D-alanine, L-alanine, DL-alanine, D-cycloserine, L-cycloserine, DL-cycloserine, a probiotic composition, taurine, nicotinamide, tryptophan, threonine, γ-aminobutyric acid (GABA), tyrosine, 5-hydroxytryptophan (5HTP), docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA), lutein, lemon balm extract, and tumeric extract.